Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in
combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable
for platinum containing chemotherapy.